Deluxe Family(SH:600503) Xin Lang Cai Jing·2025-08-25 05:51Group 1 - Huali Family plans to invest up to 300 million yuan to acquire 5%-8.09% of Haihe Pharmaceutical's shares, marking a significant move after years of inactivity in external investments [1] - Haihe Pharmaceutical has successfully commercialized three products, including Gumeitini tablets, which received conditional approval from the National Medical Products Administration in March 2023 and was included in the national medical insurance catalog [2] - The company has a strong pipeline with five products in clinical research, including a PI3Kα inhibitor, which has the potential to be the first of its kind for treating ovarian clear cell carcinoma [3] Group 2 - The domestic innovative drug industry is accelerating, with small molecule drugs maintaining an irreplaceable position in clinical treatment due to their oral convenience and controllable production costs [4] - Huali Family's investment in Haihe Pharmaceutical is a strategic move to optimize its business structure amid challenges in the real estate sector, with expectations of Haihe entering a rapid growth phase by 2027 [4] - This investment reflects Huali Family's recognition of Haihe Pharmaceutical's R&D capabilities and commercial prospects, serving as a crucial step for future business transformation [4]